If the business delivers 40M revenues and 15M EBITDA for FY21, that implies a ~6x sales and ~15x EBITDA valuation; which is certainly not expensive given the earnings momentum. Clearly they have been a beneficiary from COVID - my only question would be what happens when a vaccine is found? Would we see revenue and earnings drop to previous years?
Ann: Quarterly update and Appendix 4C, page-23
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add GSS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
72.0¢ |
Change
0.010(1.41%) |
Mkt cap ! $154.9M | |||
| Open | High | Low | Value | Volume |
| 71.0¢ | 72.5¢ | 70.5¢ | $164.1K | 229.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7500 | 71.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 72.0¢ | 21791 | 2 |
View Market Depth
| Last trade - 15.32pm 28/06/2024 (20 minute delay) ? |
| GSS (ASX) Chart |